Supernus Pharmaceuticals, Inc. — Earnings Quality Grade D
SUPN · Healthcare
Significant concerns
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO surged by 17 days (78 → 95)
AR growth 32.2% exceeds revenue growth 8.6%
Revenue 8.6%, CFFO -72.5%. Cash follows revenue
Expense Quality
Inventory growth 51.7% exceeds COGS -4.3%
CapEx growth 84.6% is >2x revenue growth 8.6%
SG&A/Gross Profit = 75.4%, exceeds 70%
Gross margin 89.6%, change +1.4pp. Stable
Cash Flow Quality
CFFO/NI = -1.23. Below 1.0
FCF $0.0B, FCF/NI = -1.19
Accruals ratio = -5.9%. Low accruals
Cash $0.3B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.7B = 65% of equity. Over 50%
Debt/EBITDA = 1.0x. Healthy
Other assets grew 107.0% vs revenue 8.6%
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change 9% YoY. Normal
Manipulation Score
M-Score = -2.54 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor SUPN continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25